Finance

Lists
P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1D
12 қаз., 09:49:20 GMT+8  ·   SGD
All symbols
SymbolPriceChange% Change
Generating top insights for P8A...
Mkt. cap
32,37 млн
Avg. vol.
1,32 мың
Volume
0,00
52-wk high
0,26 SGD
52-wk low
0,10 SGD
EPS
-0,04 SGD
Shares outstanding
267,53 млн
No. of employees
111
Mkt. cap
32,37 млн
Avg. vol.
1,32 мың
Volume
0,00
52-wk high
0,26 SGD
52-wk low
0,10 SGD
EPS
-0,04 SGD
Shares outstanding
267,53 млн
No. of employees
111
News stories
From web sources and news partners
Profile
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012. Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services. Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn. In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
About Cordlife Group Ltd
CEOYiu Pang Fai
Employees111
Founded2001 ж. 02 мам.
Headquarters-
SectorHealth care provider
Previous reportsAll values in SGD
Loading Previous Earnings...
Revenue
Net income
All values in SGD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
10,21 млн
9,46 млн
8,99 млн
8,30 млн
Cost of goods sold
4,16 млн
4,05 млн
3,78 млн
3,44 млн
Cost of revenue
4,16 млн
4,05 млн
3,78 млн
3,44 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,42 млн
10,52 млн
7,60 млн
6,41 млн
Operating expense
9,29 млн
10,41 млн
7,47 млн
6,36 млн
Total operating expenses
13,45 млн
14,46 млн
11,25 млн
9,80 млн
Operating income
-3,24 млн
-5,00 млн
-2,26 млн
-1,50 млн
Other non operating income
-
-
-
-
EBT including unusual items
-2,33 млн
-4,30 млн
-1,70 млн
-873,00 м.
EBT excluding unusual items
-2,33 млн
-4,38 млн
-1,70 млн
-873,00 м.
Income tax expense
149,00 м.
1,26 млн
19,00 мың
64,00 мың
Effective tax rate
-6,39%
-29,22%
-1,12%
-7,33%
Other operating expenses
-133,00 м.
-111,00 м.
-132,00 м.
-54,00 мың
Net income
-2,48 млн
-5,55 млн
-1,72 млн
-936,00 м.
Net profit margin
-24,32%
-58,72%
-19,13%
-11,28%
Earnings per share
-
-
-
-
Interest and investment income
642,00 м.
589,00 м.
565,00 м.
587,00 м.
Interest expense
-27,00 мың
-34,00 мың
-28,00 мың
-77,00 мың
Net interest expenses
615,00 м.
555,00 м.
537,00 м.
510,00 м.
Depreciation and amortization charges
-
-
-
-
EBITDA
-2,17 млн
-4,29 млн
-1,33 млн
-621,00 м.
Gain or loss from assets sale
1,00 мың
220,00 м.
5,00 мың
4,00 мың
AI content may include mistakes. Learn more
Google қолданбалары